Skip to main content

Medtronic Value Stock - Dividend - Research Selection

Medtronic

ISIN: IE00BTN1Y115 , WKN: A14M2J

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Medtronic plc manufactures and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. The company\'s Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; diagnostics and monitoring devices; mechanical circulatory support, TYRX, and AF products; and remote monitoring and patient-centered software. It also provides transcatheter heart valves, percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular products, and products to treat superficial and deep venous diseases. Its Minimally Invasive Therapies Group segment offers surgical care, wound closure, electrosurgical, hernia mechanical device, mesh implant, ablation, interventional lung, ventilator, capnography, airway, sensor, monitor, compression, dialysis, enteral feeding, wound care, and medical surgical products; stapling, vessel sealing, fixation, and hardware instruments; and gastrointestinal, temperature management, inhalation therapy, and renal care solutions.

 

The company\'s Restorative Therapies Group segment offers products for spine, bone graft substitutes, biologic products, trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis, as well as products to treat conditions of the ear, nose, and throat; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems; and therapies for vasculature in and around the brain. The company\'s Diabetes Group segment offers insulin pumps and consumables, continuous glucose monitoring systems, and Web-based therapy management software.

 

The company was founded in 1949 and is headquartered in Dublin, Ireland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Johnson & Johnson Is Becoming A Narrower Company Than You Bought

2026-07-25
Management's plain health care label has slipped out of the lead, and the business now on a separation clock is the one that finally started working.

Medtronic (NYSE:MDT): A Value Stock with a Discounted Valuation and Accelerating Growth

2026-07-25
Medtronic (MDT) appears in a Decent Value screen: cheap valuation, strong profitability, and improving growth outlook for value investors.

Intuitive Surgical Stock Is On Sale, But Is The Growth Story Changing?

2026-07-24
The robotic surgery leader's shares have pulled back, forcing investors to weigh a solid recovery record against new questions in its most important market.

MicroPort MedBot To Report First-Ever Profit On Booming Exports

2026-07-24
The medical robot maker expects to report a profit of 28 million yuan to 40 million yuan for the first half of 2026, reversing years of losses image credit: Bamboo Works Key Takeaways: MicroPort MedBot

6 Medical-Device Stocks to Buy After a Massive Selloff

2026-07-24
Device makers with cash flow yields of 5% to 6% now trade at a 20% to 30% discount to the S&P 500 index.

Medical-Device Stocks Are in the Bargain Bin. 6 to Buy.

2026-07-24
Device makers with cash flow yields of 5% to 6% now trade at a 20% to 30% discount to the S&P 500 index.

Medtronic Earnings Preview: What to Expect

2026-07-23
: Medtronic is set to report Q1 earnings, with analysts expecting high single-digit year-over-year EPS growth.

[Latest] Global Implantable Cardiac Fluorine-Free Resins Market Size/Share Worth USD 4.26 Billion by 2035 at a 10.8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate,SWOT Analysis)

2026-07-23
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Implantable Cardiac Fluorine-Free Resins Market size & share revenue was valued at approximately USD 1.52 Billion in 2025 and is expected to reach USD 1.67 Billion in 2026 and is expected to reach around USD 4.26 Billion by 2035, at a CAGR of 10.8% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Covestro

ISRG Growth Story Hinges on Da Vinci 5, Ion and Recurring Revenue

2026-07-22
Intuitive Surgical's growth rests on da Vinci 5, Ion, SP and digital tools as recurring revenue rises and procedure risks persist.

ISRG Trends Point to AI, Lung Biopsy Growth and Margin Pressure

2026-07-22
ISRG's growth is fueled by robotic surgery, Ion lung biopsy and AI tools, while tariffs, product mix and softer demand pressure margins.